| Project/Area Number |
24590489
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAESAWA Chihaya 岩手医科大学, 大学院医学研究科, 教授 (10326647)
AKASAKA Toshihide 岩手医科大学, 大学院医学研究科, 教授 (30137525)
SUGIYAMA Toru 岩手医科大学, 大学院医学研究科, 教授 (40162903)
KASHIWABA Masahiro 岩手医科大学, 大学院医学研究科, 講師 (80326660)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 非翻訳RNA / 腫瘍化 / lincRNA / 腫瘍 / 抗酸化関連分子 |
|---|
| Outline of Final Research Achievements |
In epithelial ovarian cancer cell lines and primary tumors, we investigated that miR-10b and/or HOTAIR can regulate the HOXD10 expression, and that it permit gain of pro-metastatic gene products. Our results suggested that downregulation of HOXD10 expression by miR-10b overexpression might induce increase of pro-metastatic gene products, such as MMP14 and RHOC, and contribute to the acquisition of metastatic phenotypes in epithelial ovarian cancer cells. Moreover, We identified a novel single-nucleotide deletion in codon 507 of exon 4 of the KEAP1 gene that resulted in a frameshift mutation in malignant melanoma. KEAP1-FSM cells exhibited significant resistance to hydrogen peroxide and anti-cancer agents such as cisplatin and dacarbazine, which are mostly used for melanoma chemotherapy. These data suggest that NRF2 may have potential value as a therapeutic target in malignant melanoma in order to improve the rate of clinical response to anti-cancer agents.
|
